HIV prevention support for people starting PrEP
Part of Immune system & allergy, Infections, Mental health clinical trials.
This study tests how to better support HIV prevention for people who inject drugs and are newly starting PrEP (medicine to prevent HIV). It focuses on people taking medication for opioid use disorder and who have mild thinking and memory problems, to help them stay safe and adhere to prevention.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years old or older
- Have opioid dependence and be newly starting or newly adherent to opioid-use-disorder medicine (methadone or buprenorphine)
- Show mild cognitive impairment on a thinking/memory test (MoCA)
- Start PrEP within the past week and be able to show proof you were prescribed it
- Have HIV-negative status based on your PrEP prescription
- Report unsafe injection practices or unprotected sex in the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps people who inject drugs start HIV prevention (PrEP) and medication for opioid use disorder (MOUD) faster. It may reduce HIV risk and improve access to treatment, while the study checks whether the “rapid access” approach works.
This study tests whether a combination of buprenorphine (a medication for opioid addiction) and PrEP (a daily pill to prevent HIV) can help people who are leaving jail or prison stay healthy. It aims to reduce both opioid relapse and HIV risk during the transition back to the community.
This study tests an integrated phone-based health program (e-health) designed for women involved with the justice system who have opioid use disorder. It aims to help people who qualify for HIV prevention (PrEP) stay protected, especially by using simple, ongoing support through phone access.
This study is for people who are HIV-negative and want to take PrEP (a daily pill that prevents HIV). It will help researchers learn more about how to best support people taking PrEP in real-world settings.
This study tests a program to help men who recently left prison and use injectable drugs start and stick with PrEP, a daily pill that prevents HIV. It aims to improve health and connect them with care.
This study helps connect young people aged 13–24 to PrEP, a daily pill that prevents HIV. It tests whether offering PrEP in clinics or community locations makes it easier for you to get and stay on this prevention medication.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.